CALIFORNIA | LOCAL
June 6, 2011 |
Physicist Rosalyn S. Yalow, who shared the 1977 Nobel Prize in Physiology or Medicine for the development of a medical diagnostic test that revolutionized patient care and led to a new understanding of diabetes and a host of other diseases, died May 30 in the Bronx, N.Y. She was 89. No cause of death was announced. Although her work in medical diagnostics was seminal, she was perhaps equally well known for her temerity in entering a field that had previously been dominated by men and for her persistence in pursuing her goals in the face of opposition from the establishment and the opposite sex. She was only the second woman to win the Nobel in medicine and only the sixth to win a Nobel in any science.
October 26, 2009 |
Simply put, diabetes is a contest between people and their blood. For people whose bodies don't produce enough insulin to manage their blood sugar, the goal is a normal blood score, achieved through a balancing act of lifestyle and medication. "Eventually most patients will follow a course of lifestyle, medications, then insulin," said Dr. Enrico Cagliero, referring to people diagnosed with the most common form of diabetes, known as Type 2. He's an endocrinologist at Massachusetts General Hospital and associate professor of medicine at Harvard Medical School.
CALIFORNIA | LOCAL
September 24, 1986 |
In the first trial studies of their kind in the United States, diabetes specialists from UC Irvine and Johns Hopkins University have been given approval by the U.S. Food and Drug Administration to surgically implant insulin pumps, UCI officials said Tuesday.
CALIFORNIA | LOCAL
August 20, 1990 |
An experimental transplant operation designed to free diabetics from insulin injections has produced the most promising results since the technique was developed, researchers reported last week. The procedure enabled five of nine patients to significantly reduce their need for daily insulin injections, including one 16-year-old Louisville, Ky., girl who has remained completely independent of injections for more than six months, the researchers reported. "I'm completely excited," said Dr.
November 1, 2010 |
Every night, Edward Damiano wakes three to four times to monitor his 11-year-old son's blood sugar levels. Damiano administers insulin remotely through a pump when his son's blood sugar reading is high or gives him juice through a straw when his blood sugar falls. His son, David, who was diagnosed with Type 1 diabetes at 11 months old, sleeps peacefully through it all ? and that's exactly what worries Damiano. "You can check his blood sugar all night long and he won't wake up," Damiano says.
December 1, 2011 |
On Thursday the Food and Drug Administration issued draft guidelines for researchers and manufacturers working to develop and build an artificial pancreas to help patients with Type 1 diabetes control their blood sugar. About 3 million Americans have Type 1 diabetes, which develops when cells in the pancreas stop producing enough insulin to control blood sugar. Patients with the disease must monitor their blood glucose aggressively. If it goes too high, they have to carefully calculate how much insulin they need to bring it in line -- and then get an injection. If a person with Type 1 diabetes' blood sugar drops too low, he or she could require a dose of another hormone, glucagon, to raise it back up. The unrelenting and error-prone process can be exhausting, so patient advocacy groups such as the Juvenile Diabetes Research Foundation have been pushing the development of an artificial pancreas that would tightly control blood sugar levels much as the actual organ: monitoring glucose levels continually and automatically delivering the right dose of insulin, through a pump, into the body. The system would work by connecting the monitoring system to a computer, which in turn would calculate the correct insulin dose and send a signal to the insulin pump to deliver the needed hormones.
March 19, 2012 |
Diabetes affects more than 25 million Americans. New medications and strategies to treat the disease are greatly needed. But the jury is still out on the experimental medication dapagliflozin. The medication looks to have significant benefits and risks, according to a study published Monday. Dapagliflozin is being developed by Bristol-Myers-Squibb Co. in partnership with AstraZeneca. It represents a new class of diabetes medications called selective renal sodium glucose contransporter inhibitors.